Market Closed -
Japan Exchange
07:00:00 12/06/2024 BST
5-day change
1st Jan Change
1,586
JPY
-2.40%
-3.35%
+12.88%
Santen Pharmaceutical Co., Ltd. Provides Financial Guidance for the Fiscal Year Ending March 31, 2022
Santen Pharmaceutical Co., Ltd. provided financial guidance for the fiscal year ending March 31, 2022. For the period, the company expected revenue of JPY 260,000 million, Operating profit of JPY 41,500 million, Net profit for the year of JPY 30,500 million and Basic EPS of JPY 77.07.
Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares
05-10
MT
Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.
05-09
CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025
05-09
CI
Santen Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
05-08
CI
Santen Pharmaceutical to Cancel 12 Million Treasury Shares
03-26
MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024
03-25
CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
03-25
CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.
03-21
CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy
01-29
MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen
01-08
MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
01-05
CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares
12-04
MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast
11-08
MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
11-07
CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September
03/10/23
MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.
02/10/23
CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy
21/09/23
MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
20/09/23
CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
03/08/23
CI
Santen Disposes of Shares as Restricted Stock-Linked Remuneration/Restricted Stock
24/07/23
MT
Visiox Pharma Enters into A Definitive Agreement with Santen Pharmaceutical Co., Ltd to License OMLONTI
19/07/23
CI
Bank Earnings Leave Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday
19/07/23
MT
Harrow Health Acquires Certain US, Canada Rights to Santen Pharmaceutical's Ophthalmic Portfolio
19/07/23
MT
Santen Pharmaceutical Co., Ltd. Signs Licensing Agreements
18/07/23
CI
Jefferies Adjusts Santen Pharmaceutical's Price Target to 1,400 Yen From 1,300 Yen, Keeps at Buy
12/07/23
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
More about the company
Last Close Price
1,625
JPY
Average target price
1,827
JPY
Spread / Average Target
+12.43%
Consensus
1st Jan change
Capi.
+12.88% 3.71B +48.53% 780B +41.28% 627B +20.93% 334B +8.21% 296B +17.83% 244B -0.86% 217B +11.48% 214B +4.40% 161B -2.64% 159B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1